Cantuzumab ravtansine

Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454) . Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2].

Product Specifications

CAS Number

[868747-45-9]

Product Name Alternative

IMGN242; huC242-DM4

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Microtubule/Tubulin

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cantuzumab-ravtansine.html

Purity

98.71

Solubility

10 mM in DMSO

Smiles

[Cantuzumabravtansine]

Molecular Weight

150000 (average)

References & Citations

[1]Robert J. Lutz, et al. HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice. Cancer Res (2005) 65 (9_Supplement) : 334-335.|[2]Olga Ab, et al. Activity of huC242-DM4, an antibody-cytotoxic agent conjugate, used in combination with anti-neoplastic agents against gastric cancer cells in culture. Mol Cancer Ther (2007) 6 (11_Supplement) : A127.